217 related articles for article (PubMed ID: 20726858)
1. Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer.
Yotsumoto F; Fukami T; Yagi H; Funakoshi A; Yoshizato T; Kuroki M; Miyamoto S
Cancer Sci; 2010 Nov; 101(11):2351-60. PubMed ID: 20726858
[TBL] [Abstract][Full Text] [Related]
2. Amphiregulin-EGFR signaling mediates the migration of bone marrow mesenchymal progenitors toward PTH-stimulated osteoblasts and osteocytes.
Zhu J; Siclari VA; Liu F; Spatz JM; Chandra A; Divieti Pajevic P; Qin L
PLoS One; 2012; 7(12):e50099. PubMed ID: 23300521
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
El-Rayes BF; Ali S; Ali IF; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2006 Nov; 66(21):10553-9. PubMed ID: 17079479
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
5. Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin.
Rittié L; Kansra S; Stoll SW; Li Y; Gudjonsson JE; Shao Y; Michael LE; Fisher GJ; Johnson TM; Elder JT
Am J Pathol; 2007 Jun; 170(6):2089-99. PubMed ID: 17525275
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Yokoi K; Fidler IJ
Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
[TBL] [Abstract][Full Text] [Related]
7. Validation of HB-EGF and amphiregulin as targets for human cancer therapy.
Yotsumoto F; Yagi H; Suzuki SO; Oki E; Tsujioka H; Hachisuga T; Sonoda K; Kawarabayashi T; Mekada E; Miyamoto S
Biochem Biophys Res Commun; 2008 Jan; 365(3):555-61. PubMed ID: 18023415
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models.
Rabia E; Garambois V; Hubert J; Bruciamacchie M; Pirot N; Delpech H; Broyon M; Theillet C; Colombo PE; Vie N; Tosi D; Gongora C; Khellaf L; Jarlier M; Radosevic-Robin N; Chardès T; Pèlegrin A; Larbouret C
MAbs; 2021; 13(1):1914883. PubMed ID: 33876707
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells.
Eckstein N; Servan K; Girard L; Cai D; von Jonquieres G; Jaehde U; Kassack MU; Gazdar AF; Minna JD; Royer HD
J Biol Chem; 2008 Jan; 283(2):739-50. PubMed ID: 17942395
[TBL] [Abstract][Full Text] [Related]
11. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Ng SS; Tsao MS; Nicklee T; Hedley DW
Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
[TBL] [Abstract][Full Text] [Related]
12. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
13. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
[TBL] [Abstract][Full Text] [Related]
14. Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways.
Li W; Wang Z; Xiao X; Han L; Wu Z; Ma Q; Cao L
Oncol Rep; 2019 Jan; 41(1):650-658. PubMed ID: 30542713
[TBL] [Abstract][Full Text] [Related]
15. ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
Teixidó C; Arguelaguet E; Pons B; Aracil M; Jimeno J; Somoza R; Marés R; Ramón Y Cajal S; Hernández-Losa J
Int J Oncol; 2012 Jul; 41(1):317-24. PubMed ID: 22485250
[TBL] [Abstract][Full Text] [Related]
16. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
Camblin AJ; Pace EA; Adams S; Curley MD; Rimkunas V; Nie L; Tan G; Bloom T; Iadevaia S; Baum J; Minx C; Czibere A; Louis CU; Drummond DC; Nielsen UB; Schoeberl B; Pipas JM; Straubinger RM; Askoxylakis V; Lugovskoy AA
Clin Cancer Res; 2018 Jun; 24(12):2873-2885. PubMed ID: 29549161
[No Abstract] [Full Text] [Related]
17. Suppression of amphiregulin/epidermal growth factor receptor signals contributes to the protective effects of quercetin in cirrhotic rats.
Cuevas MJ; Tieppo J; Marroni NP; Tuñón MJ; González-Gallego J
J Nutr; 2011 Jul; 141(7):1299-305. PubMed ID: 21562239
[TBL] [Abstract][Full Text] [Related]
18. Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-β-induced pulmonary fibrosis.
Zhou Y; Lee JY; Lee CM; Cho WK; Kang MJ; Koff JL; Yoon PO; Chae J; Park HO; Elias JA; Lee CG
J Biol Chem; 2012 Dec; 287(50):41991-2000. PubMed ID: 23086930
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Kimple RJ; Vaseva AV; Cox AD; Baerman KM; Calvo BF; Tepper JE; Shields JM; Sartor CI
Clin Cancer Res; 2010 Feb; 16(3):912-23. PubMed ID: 20103665
[TBL] [Abstract][Full Text] [Related]
20. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
